Physician profile
Mark T Eggleston
NPI 1306836705
$1,028.93
in general payments reported to CMS, 2019-2025
13 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $131 · 2021: $89.99 · 2022: $32.30 · 2023: $110 · 2024: $189 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $176.98 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $150.04 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $127.07 | 2019-2023 | Cequa |
| Leadiant Biosciences, INC. | $101.64 | 2023-2024 | Cystaran |
| Astellas Pharma US INC | $92.95 | 2023-2025 | Izervay |
| Allergan, INC. | $91.52 | 2020-2021 | |
| Abbvie INC. | $67.83 | 2024-2025 | |
| Abiomed | $65.67 | 2024 | Impella |
| Alcon Vision LLC | $51.15 | 2021-2025 | Clareon |
| Rayner Intraocular Lenses Limited | $45.30 | 2023-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Aerie Pharmaceuticals, INC. | $26.48 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $20.34 | 2022 | |
| Oyster Point Pharma, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Eggleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.